UNSPSC 51392216: Tramazoline

This classification denotes an alpha-adrenergic agonist with the molecular formula C13H17N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLE31693IV, chemically known as 4,5-dihydro-n-(5,6,7,8-tetrahydro-1-naphthalenyl)-1h-imidazol-2-amine but generally known as tramazoline, which bears US NIH Compound Identifier 5524. European Medicines Agency schedules Tramazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11211MIG. The term TRAMAZOLINE is an International Non-Proprietary Name.

UNSPSC 51392216 Tramazoline, a Commodity code, covers pharmaceutical products and related health systems procured by state and local governments to support public health and emergency response initiatives. The code encompasses naloxone delivery products, drug deactivation systems, and direct-to-manufacturer prescription fulfillment arrangements that state health agencies and county health departments are actively acquiring. Recent solicitations show state and local buying bodies sourcing both point-of-use pharmaceutical supplies and strategic pharmacy benefit program infrastructure, with a focus on community health support and opioid response capabilities.

Activity under this code spans state health agencies and county health departments. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, using a fixed-fee model and including a three-month probationary period. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) in April 2026 to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, focused on direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager channels. Florida and Texas represent the primary geographic footprint in recent postings. The naloxone procurement indicates active state and local investment in emergency opioid response infrastructure, while the Texas RFI signals emerging interest in alternative pharmacy sourcing models that bypass conventional wholesaler and PBM intermediaries.